8:45am ET
Investing
AbbVie Just Paid Investors: Here’s How Much They Received
AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 years.
NVO Coverage Page 8
12:01pm ET
Investing
I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game
The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough to gauge which innovative biotech firms will have…
11:15am ET
Investing
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
Eli Lilly (NYSE: LLY | LLY Price Prediction) doesn’t really need much of an introduction. It has become a household name due to its obesity and diabetes treatments. LLY stock has delivered…
3:15pm ET
Investing
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert
Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) has been described as the best pure-play stock in artificial intelligence. The market agrees, sending shares of PLTR stock some 342% higher over the past…
9:06am ET
Investing
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly (NYSE:LLY | LLY Price Prediction) has become the industry leader in a…
8:58am ET
Investing
Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones?
The Dow Jones is one of Wall Street’s most iconic benchmarks and it tracks 30 of America’s largest companies. It was made over 128 years ago but is still relevant and a…
11:12am ET
Investing
These 3 Stocks Are Winning Thanks to Baby Boomers
According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S. increasing their year-over-year…
7:53pm ET
Investing
Is John Paulson’s Best Investment Ever a Buy or Sell
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
9:15am ET
Investing
Prediction: This Will Be the Biggest Pharma Stock in 10 Years
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
11:42am ET
Investing
Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who…
11:50am ET
Investing
Five Top Obesity Stocks to Buy and Hold Long Term
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
2:40pm ET
Investing
2 Weight Loss Drug Stocks Worth Stashing Away for Years
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and GLP-1 (weight-loss)…
12:32pm ET
Investing
2 Biotech Bets to Buy in September
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery process is…
7:43am ET
Investing
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA | NVDA Price Prediction) to the forefront of the industry.…
4:37pm ET
Investing
Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs…